Scopus Biopharma Stock Current Valuation
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Valuation analysis of Scopus Biopharma helps investors to measure Scopus Biopharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Scopus Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Scopus Biopharma is based on 3 months time horizon. Increasing Scopus Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Scopus otc stock is determined by what a typical buyer is willing to pay for full or partial control of Scopus Biopharma. Since Scopus Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Scopus OTC Stock. However, Scopus Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.1 | Real 0.0893 | Hype 0.1 |
The intrinsic value of Scopus Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Scopus Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Scopus Biopharma helps investors to forecast how Scopus otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Scopus Biopharma more accurately as focusing exclusively on Scopus Biopharma's fundamentals will not take into account other important factors: Scopus Biopharma OTC Stock Current Valuation Analysis
Scopus Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Scopus Biopharma Current Valuation | 1.18 M |
Most of Scopus Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scopus Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Scopus Biopharma has a Current Valuation of 1.18 M. This is 99.99% lower than that of the Healthcare sector and 99.97% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Scopus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in current valuation category among its peers.
Scopus Fundamentals
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 | ||||
| Current Valuation | 1.18 M | ||||
| Shares Outstanding | 21.09 M | ||||
| Shares Owned By Insiders | 50.66 % | ||||
| Shares Owned By Institutions | 2.15 % | ||||
| Number Of Shares Shorted | 23.77 K | ||||
| Price To Book | 2.42 X | ||||
| EBITDA | (26.18 M) | ||||
| Net Income | (26.95 M) | ||||
| Cash And Equivalents | 1.16 M | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 2.54 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (0.26) X | ||||
| Cash Flow From Operations | (11.42 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (1.51) X | ||||
| Target Price | 12.0 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 2.17 M | ||||
| Total Asset | 8.19 M | ||||
| Z Score | -9.9 | ||||
| Net Asset | 8.19 M |
About Scopus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scopus Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scopus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scopus Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Correlations Find global opportunities by holding instruments from different markets |